文献速递胸部肿瘤放疗放疗物理与技术

早期非小细胞肺癌合并间质性肺病患者的治疗相关毒性:系统综述

Treatment-Related Toxicity in Patients With Early-Stage Non-Small Cell Lung Cancer and Coexisting Interstitial Lung Disease: A Systematic Review.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-03-15

该系统综述汇总了早期非小细胞肺癌合并间质性肺病患者接受根治性治疗后的治疗相关死亡率和ILD特异性毒性。主要医学不可手术患者中,SABR的治疗相关死亡率为15.6%、ILD特异性毒性为25%,粒子束治疗分别为4.3%和18.2%,射频消融分别为8.7%和25%;手术患者分别为2.2%和12%。SABR剂量参数V20≤6.5%和平均肺剂量≤4.5 Gy与死亡率降低相关。

要点

  • 医学不可手术的ES-NSCLC合并ILD患者接受SABR、粒子束或RFA时治疗相关死亡率高。
  • SABR组治疗相关死亡率为15.6%、ILD特异性毒性为25%。
  • SABR的V20≤6.5%和平均肺剂量≤4.5 Gy与死亡率降低相关。

核心结论

  • 在主要医学不可手术的早期非小细胞肺癌合并间质性肺病患者中,SABR、粒子束治疗和射频消融均观察到持续高水平的治疗相关死亡率和ILD特异性毒性。
  • 对此类患者,应考虑在高毒性发生率和总体预后不良的背景下权衡根治性治疗。

研究设计与样本

  • 系统综述,检索MEDLINE和Embase数据库从建库至2016年1月,纳入接受根治性治疗的早期非小细胞肺癌患者研究。
  • 共审查3056条记录,最终纳入50篇期刊文章进行数据提取。
  • 结果按各研究样本量加权比例汇总。

主要发现

  • 主要医学不可手术患者中,SABR的治疗相关死亡率为15.6%、ILD特异性毒性为25%。
  • 粒子束治疗的治疗相关死亡率为4.3%、ILD特异性毒性为18.2%。
  • 射频消融的治疗相关死亡率为8.7%、ILD特异性毒性为25%。
  • 医学可手术患者接受手术的治疗相关死亡率为2.2%、ILD特异性毒性为12%。
  • SABR剂量参数分析中,V20≤6.5%和平均肺剂量≤4.5 Gy与死亡率降低相关。

关键数值与推荐

  • SABR:治疗相关死亡率15.6%,ILD特异性毒性25%。
  • 粒子束治疗:治疗相关死亡率4.3%,ILD特异性毒性18.2%。
  • 射频消融:治疗相关死亡率8.7%,ILD特异性毒性25%。
  • 手术:治疗相关死亡率2.2%,ILD特异性毒性12%。
  • SABR剂量参数:V20≤6.5%和平均肺剂量≤4.5 Gy与死亡率降低相关。

临床怎么用

  • 对早期非小细胞肺癌合并间质性肺病患者选择根治性治疗时,应充分告知高治疗相关死亡率和ILD特异性毒性风险。
  • SABR计划时可考虑将V20控制在≤6.5%、平均肺剂量控制在≤4.5 Gy以降低死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Definitive treatment for patients with early-stage non-small cell lung cancer (ES-NSCLC) is usually well tolerated. Patients with ES-NSCLC and coexisting interstitial lung disease (ILD) are at increased risk of severe treatment-related toxicity after definitive therapy. The main objective of this systematic review is to provide a pooled estimation of treatment-related mortality and ILD-specific toxicity in this population of patients and to identify trends for further study. METHODS AND MATERIALS: The MEDLINE and Embase databases were queried from respective dates of inception to January 2016. Studies that included patients who underwent definitive treatment for ES-NSCLC not combined with other treatments were included. Patients with oligometastases who were treated with aggressive palliation were included if it did not constitute the majority of patients in a specific study. The results were summarized with weighted proportions according to the sample size of individual studies. RESULTS: Overall, 3056 records were reviewed and 50 journal articles were included in the abstraction. The weighted proportion of treatment-related mortality (and ILD-specific toxicity) in primarily medically inoperable patients was as follows: stereotactic ablative radiation therapy (SABR) 15.6% (25%), particle beam therapy 4.3% (18.2%) and radiofrequency ablation (RFA) 8.7% (25%). The data for medically operable patients who underwent surgery were extracted for reference. Treatment-related mortality and ILD-specific toxicity were 2.2% and 12%, respectively, in the surgical population. On analysis of reported SABR dose parameters, V20 ≤ 6.5% and mean lung dose ≤4.5 Gy were found to be metrics associated with reduced mortality. CONCLUSION: A consistently high level of treatment-related mortality and ILD-specific toxicity was observed in primarily medically inoperable patients treated with SABR, particle beam therapy, and RFA. For these patients, curative treatment should be considered in the context of the high toxicity rates and overall poor prognosis. Stringent radiation dosimetric parameters may result in reduced toxicity.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Chen H, Senan S, Nossent EJ, et al. Treatment-Related Toxicity in Patients With Early-Stage Non-Small Cell Lung Cancer and Coexisting Interstitial Lung Disease: A Systematic Review. Int J Radiat Oncol Biol Phys. 2017. PMID: 28581404. doi:10.1016/j.ijrobp.2017.03.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。